Media coverage
1
Media coverage
Title Onconova Therapeutics initiates phase 1/2a study of rigosertib plus nivolumab to treat KRAS+ lung adenocarcinoma Media name/outlet PharmaBiz Country/Territory India Date 24/06/20 Persons Rajwanth Veluswamy
Onconova Therapeutics initiates phase 1/2a study of rigosertib plus nivolumab to treat KRAS+ lung adenocarcinoma
- Cancer Prevention & Control
- Medicine - Hematology and Medical Oncology
- KL2
- CTSA ConduITS - Institutes for Translational Sciences
- Cancer Clinical Investigation
- Institute for Translational Epidemiology at the Icahn School of Medicine at Mount Sinai
- Medicine
- The Tisch Cancer Institute
- Icahn School of Medicine at Mount Sinai
Press/Media